WO2006038185A3 - Use of the staudinger ligation in imaging and therapy end kits for imaging and therapy - Google Patents

Use of the staudinger ligation in imaging and therapy end kits for imaging and therapy Download PDF

Info

Publication number
WO2006038185A3
WO2006038185A3 PCT/IB2005/053258 IB2005053258W WO2006038185A3 WO 2006038185 A3 WO2006038185 A3 WO 2006038185A3 IB 2005053258 W IB2005053258 W IB 2005053258W WO 2006038185 A3 WO2006038185 A3 WO 2006038185A3
Authority
WO
WIPO (PCT)
Prior art keywords
imaging
therapy
targeted
staudinger ligation
ligation
Prior art date
Application number
PCT/IB2005/053258
Other languages
French (fr)
Other versions
WO2006038185A2 (en
Inventor
Marc S Robillard
Holger Gruell
Original Assignee
Koninkl Philips Electronics Nv
Marc S Robillard
Holger Gruell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Koninkl Philips Electronics Nv, Marc S Robillard, Holger Gruell filed Critical Koninkl Philips Electronics Nv
Priority to EP05788346A priority Critical patent/EP1799273A2/en
Priority to JP2007535308A priority patent/JP2008515876A/en
Priority to US11/576,536 priority patent/US20080181847A1/en
Publication of WO2006038185A2 publication Critical patent/WO2006038185A2/en
Publication of WO2006038185A3 publication Critical patent/WO2006038185A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

The use of a selective chemical and bioorthogonal reaction providing a covalent ligation such as the Staudinger ligation, in targeted molecular imaging and therapy is presented, more specifically with interesting applications for pre-targeted imaging or therapy. Current pre-targeted imaging is hampered by the fact that it relies solely on natural/biological targeting constructs (i.e. biotin/streptavidin). Size considerations and limitations associated with their endogenous nature severely limit the number of applications. The present invention describes how the use of an abiotic, bio-orthogonal reaction which forms a stable adduct under physiological conditions, by way of a small or undetectable bond, can overcome these limitations.
PCT/IB2005/053258 2004-10-07 2005-10-04 Use of the staudinger ligation in imaging and therapy end kits for imaging and therapy WO2006038185A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP05788346A EP1799273A2 (en) 2004-10-07 2005-10-04 Use of the staudinger ligation in imaging and therapy end kits for imaging and therapy
JP2007535308A JP2008515876A (en) 2004-10-07 2005-10-04 Use of Staudinger ligation in imaging and therapy end kits for imaging and therapy
US11/576,536 US20080181847A1 (en) 2004-10-07 2005-10-04 Targeted Imaging and/or Therapy Using the Staudinger Ligation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04104913 2004-10-07
EP04104913.1 2004-10-07

Publications (2)

Publication Number Publication Date
WO2006038185A2 WO2006038185A2 (en) 2006-04-13
WO2006038185A3 true WO2006038185A3 (en) 2006-07-13

Family

ID=35539273

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/IB2005/053258 WO2006038185A2 (en) 2004-10-07 2005-10-04 Use of the staudinger ligation in imaging and therapy end kits for imaging and therapy
PCT/IB2005/053257 WO2006038184A2 (en) 2004-10-07 2005-10-04 Compounds, kits and methods for use in medical imaging

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/053257 WO2006038184A2 (en) 2004-10-07 2005-10-04 Compounds, kits and methods for use in medical imaging

Country Status (5)

Country Link
US (2) US20080075661A1 (en)
EP (2) EP1799273A2 (en)
JP (2) JP2008515875A (en)
CN (2) CN101035565A (en)
WO (2) WO2006038185A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0428012D0 (en) 2004-12-22 2005-01-26 Hammersmith Imanet Ltd Radiolabelling methods
EP1894577A4 (en) * 2005-06-14 2012-03-28 Nihon Mediphysics Co Ltd Radioactive diagnostic imaging agent
JP2009512642A (en) * 2005-10-04 2009-03-26 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ Staudinger reaction in imaging and therapy and kits used for imaging and therapy
RU2459866C2 (en) 2005-10-12 2012-08-27 Зе Скрипс Ресеч Инститьют Selective post-translational modification of phage-displayed polypeptides
WO2007047668A2 (en) * 2005-10-14 2007-04-26 California Institute Of Technology Use of non-canonical amino acids as metabolic markers for rapidly-dividing cells
US7910335B2 (en) * 2005-10-27 2011-03-22 President And Fellows Of Harvard College Methods and compositions for labeling nucleic acids
DK1991273T4 (en) 2006-02-10 2022-02-07 Life Technologies Corp LABELING AND DETECTION OF POST-TRANSLATIONALLY MODIFIED PROTEINS
US8114636B2 (en) 2006-02-10 2012-02-14 Life Technologies Corporation Labeling and detection of nucleic acids
RU2008142542A (en) * 2006-03-28 2010-05-10 Конинклейке Филипс Электроникс Н.В. (Nl) APPLICATION OF STUDINGER LIGATION IN THE IN VIVO ASSEMBLY OF A BIOLOGICALLY ACTIVE COMPOUND
MX2009009291A (en) * 2007-03-01 2009-12-14 Bayer Schering Pharma Ag Radio fluoridation methods.
CN101925366B (en) 2007-11-21 2015-02-04 乔治亚大学研究基金公司 Alkynes and methods of reacting alkynes with 1,3-dipole-functional compounds
CN102119223A (en) 2008-05-16 2011-07-06 生命技术公司 Dual labeling methods for measuring cellular proliferation
EP2300601A1 (en) * 2008-07-14 2011-03-30 Koninklijke Philips Electronics N.V. Process for providing an assembly of cell microcarriers
EP2361098B1 (en) 2008-10-31 2019-08-28 The General Hospital Corporation Compositions and methods for delivering a substance to a biological target
DE102009012640A1 (en) 2009-03-09 2010-09-30 Freie Universität Berlin Phosphoamidate group modified compound and its use
JP5594742B2 (en) * 2009-05-15 2014-09-24 独立行政法人理化学研究所 18F labeled azide compound, 18F labeling reagent, and 18F labeling method for alkyne compound using the same
EP2552861A1 (en) * 2010-03-29 2013-02-06 Siemens Medical Solutions USA, Inc. Application of staudinger ligation in pet imaging
US9649394B2 (en) 2010-11-22 2017-05-16 The General Hospital Corporation Compositions and methods for in vivo imaging
JP5992435B2 (en) 2010-12-21 2016-09-14 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． Remover of biomolecules from circulation
WO2012121746A2 (en) 2011-03-09 2012-09-13 The General Hospital Corporation Imaging beta cell mass
DE102011109187A1 (en) 2011-08-02 2013-02-07 Aptenia Srl Conjugation agent useful e.g. for bioassay and in medical diagnosis, comprises protected Staudinger component that is convertible into unprotected Staudinger component before conjugation reaction, and is linked with carrier by spacer group
WO2014065860A1 (en) 2012-10-24 2014-05-01 The General Hospital Corporation Functionalized 1,2,4,5-tetrazine compounds for use in bioorthogonal coupling reactions
WO2014182704A2 (en) 2013-05-06 2014-11-13 The General Hospital Corporation Bioorthogonal turn-on probes
DE102013224412A1 (en) * 2013-11-28 2015-05-28 Leica Microsystems Cms Gmbh Method for examining a sample by CARS microscopy
EA033889B1 (en) 2014-01-21 2019-12-05 Янссен Фармацевтика Нв Combination comprising sv2a ligand and positive allosteric modulator of metabotropic glutamatergic receptor subtype 2
ES2860298T3 (en) 2014-01-21 2021-10-04 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators of metabotropic glutamatergic receptor subtype 2 and their use
CN106890345B (en) * 2015-12-17 2020-09-01 中国科学院苏州纳米技术与纳米仿生研究所 Contrast agent molecule targeting mitochondria as T2Use of contrast agents
WO2019151128A1 (en) * 2018-02-05 2019-08-08 国立大学法人 宮崎大学 Cell labeling agent and cell labeling kit
US11224666B2 (en) * 2018-02-14 2022-01-18 Boston Scientific Scimed, Inc. Gadolinium contrast agents, scavenging methods, and scavenging system
WO2019177740A1 (en) * 2018-03-12 2019-09-19 Boston Scientific Scimed, Inc. Scavenging methods, and scavenging system for radiocontrast agents

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987002708A1 (en) * 1985-10-24 1987-05-07 Siska Diagnostics, Inc. Lanthanide chelate-tagged nucleic acid probes
WO1989004375A1 (en) * 1987-10-23 1989-05-18 Siska Diagnostics, Inc. Lanthanide chelate-tagged nucleic acid probes
EP0659764A2 (en) * 1993-12-21 1995-06-28 SORIN BIOMEDICA S.p.A. Peptides modified by the phosphine group for marking with 99mTC and 186-188Re or paramagnetic agents
US5948386A (en) * 1997-03-14 1999-09-07 The Curators Of The University Of Missouri Conjugate and method for forming aminomethyl phosphorus conjugates
WO2001068565A2 (en) * 2000-03-16 2001-09-20 The Regents Of The University Of California Chemoselective ligation by use of a phosphine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) * 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US5326856A (en) * 1992-04-09 1994-07-05 Cytogen Corporation Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding
US5608060A (en) * 1992-06-09 1997-03-04 Neorx Corporation Biotinidase-resistant biotin-DOTA conjugates
IL106692A (en) * 1993-08-13 1997-04-15 Israel Atomic Energy Comm AZIDOALKYL DERIVATIVES AND THEIR USE FOR THE PREPARATION OF 99mTc COMPLEXES FOR IMAGING
US6770261B2 (en) * 1995-06-02 2004-08-03 Research Corporation Technologies Magnetic resonance imaging agents for the detection of physiological agents
AU709345B2 (en) * 1995-09-07 1999-08-26 Emory University Therapeutic azide compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987002708A1 (en) * 1985-10-24 1987-05-07 Siska Diagnostics, Inc. Lanthanide chelate-tagged nucleic acid probes
WO1989004375A1 (en) * 1987-10-23 1989-05-18 Siska Diagnostics, Inc. Lanthanide chelate-tagged nucleic acid probes
EP0659764A2 (en) * 1993-12-21 1995-06-28 SORIN BIOMEDICA S.p.A. Peptides modified by the phosphine group for marking with 99mTC and 186-188Re or paramagnetic agents
US5948386A (en) * 1997-03-14 1999-09-07 The Curators Of The University Of Missouri Conjugate and method for forming aminomethyl phosphorus conjugates
WO2001068565A2 (en) * 2000-03-16 2001-09-20 The Regents Of The University Of California Chemoselective ligation by use of a phosphine

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CAI JIANFENG ET AL: "Nucleic acid-triggered fluorescent probe activation by the Staudinger reaction.", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY. 22 DEC 2004, vol. 126, no. 50, 22 December 2004 (2004-12-22), pages 16324 - 16325, XP002363183, ISSN: 0002-7863 *
GOLOLOBOY Y G ET AL: "SIXTY YEARS OF STAUDINGER REACTION", TETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 37, 1981, pages 437 - 472, XP001026177, ISSN: 0040-4020 *
GOODWIN D A: "Tumor Pretargeting: Almost the Bottom Line", JOURNAL OF NUCLEAR MEDICINE, SOCIETY OF NUCLEAR MEDICINE, RESTON, VA, US, vol. 36, no. 5, May 1995 (1995-05-01), pages 876 - 879, XP002100555, ISSN: 0161-5505 *
KIICK K L ET AL: "Incorporation of azides into recombinant proteins for chemoselective modification by the Staudinger ligation", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 99, no. 1, 8 January 2002 (2002-01-08), pages 19 - 24, XP002904363, ISSN: 0027-8424 *
LEMIEUX GEORGE A ET AL: "A fluorogenic dye activated by the staudinger ligation.", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY. 23 APR 2003, vol. 125, no. 16, 23 April 2003 (2003-04-23), pages 4708 - 4709, XP002363184, ISSN: 0002-7863 *
PAGANELLI G ET AL: "MONOCLONAL ANTIBODY PRETARGETING TECHNIQUES FOR TUMOUR LOCALIZATIONTHE AVIDIN-BIOTIN SYSTEM", NUCLEAR MEDICINE COMMUNICATIONS, vol. 12, no. 3, 1 March 1991 (1991-03-01), pages 211 - 234, XP000373577, ISSN: 0143-3636 *
PRESCHER JENNIFER A ET AL: "Chemical remodelling of cell surfaces in living animals.", NATURE. 19 AUG 2004, vol. 430, no. 7002, 19 August 2004 (2004-08-19), pages 873 - 877, XP002363185, ISSN: 1476-4687 *
RENN O ET AL: "NEW APPROACHES TO DELIVERING METAL-LABELED ANTIBODIES TO TUMORS: SYNTHESIS AND CHARACTERIZATION OF NEW BIOTINYL CHELATE CONJUGATES FOR PRE-TARGETED DIAGNOSIS AND THERAPY", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 39, no. 2/3, 1 May 1996 (1996-05-01), pages 239 - 249, XP000589686, ISSN: 0168-3659 *
SEN GUPTA SAYAM ET AL: "Accelerated bioorthogonal conjugation: a practical method for the ligation of diverse functional molecules to a polyvalent virus scaffold.", BIOCONJUGATE CHEMISTRY. 2005 NOV-DEC, vol. 16, no. 6, November 2005 (2005-11-01), pages 1572 - 1579, XP002362784, ISSN: 1043-1802 *

Also Published As

Publication number Publication date
US20080075661A1 (en) 2008-03-27
JP2008515876A (en) 2008-05-15
WO2006038184A2 (en) 2006-04-13
EP1809339A2 (en) 2007-07-25
WO2006038185A2 (en) 2006-04-13
CN101068577A (en) 2007-11-07
EP1799273A2 (en) 2007-06-27
JP2008515875A (en) 2008-05-15
CN101035565A (en) 2007-09-12
WO2006038184A3 (en) 2006-06-22
US20080181847A1 (en) 2008-07-31

Similar Documents

Publication Publication Date Title
WO2006038185A3 (en) Use of the staudinger ligation in imaging and therapy end kits for imaging and therapy
WO2007039858A3 (en) Targeted imaging and/or therapy using the [3+2] azide-alkyne cycloaddition
WO2007112193A3 (en) Camptothecin-binding moiety conjugates
WO2003020949A3 (en) Targeted nucleic acid constructs and uses related thereto
WO2004064595A3 (en) Multivalent constructs for therapeutic and diagnostic applications
WO2009100194A3 (en) Camptothecin-binding moiety conjugates
WO2007133290A3 (en) Anti-ox40l antibodies and methods using same
WO2007011813A3 (en) Balanced ultrasonic curved blade
WO2007130697A8 (en) Anti-ephb4 antibodies and methods using same
WO2006083936A3 (en) Anti-ephb2 antibodies and methods using same
WO2007105027A8 (en) Anticancer drugs conjugated to antibody via an enzyme cleavable linker
WO2008033804A3 (en) Quantum dot barcode structures and uses thereof
TW200706689A (en) Gas providing member and processing device
WO2008064910A3 (en) Metastasis-specific peptides and their diagnostic and therapeutic applications
TW200626737A (en) Tubular sputtering target
WO2004100926A3 (en) Delivery of agents using hydrolyzable leaving groups
WO2007127506A8 (en) Anti-ephrinb2 antibodies and methods using same
WO2007027796A3 (en) Proximity ligation assays with peptide conjugate 'burrs' and aptamers for the sensitive detection of spores and cancer cells
MA31014B1 (en) VACCINE AGAINST LEISHMANIA CANINE.
WO2006072607A3 (en) Transplastomic plants free of the selectable marker gene
WO2008126613A1 (en) Actuator body and throttle mechanism
WO2008036953A8 (en) In vivo transformation of pancreatic acinar cells into insulin-producing cells
WO2006119997A3 (en) Treatment probe
WO2006017857A3 (en) Antibiotic resistance free dna vaccines
MX2010006509A (en) Herbicidal formulations for triethanolamine salts of glyphosate.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005788346

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11576536

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1400/CHENP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2007535308

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 200580034471.3

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 2005788346

Country of ref document: EP